Showing 712 results
-
Press release /PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
-
Press release /Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with…
-
Press release /Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
-
Story /Improving the patient experience and removing potential barriers to clinical trial participation
-
Story /Jordan, a melanoma survivor, shares her experience with melanoma, BRAF mutation testing and the importance of patient empowerment.
-
Story /Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
-
Story /Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
-
Story /Researchers race to put hydroxychloroquine to the test in a large study.
-
Press release /Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…